Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Jun 10, 2023 4:28pm

108 Views

Post# 35490165

RE:RE:RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

Patents cliff, bold acquisition, 10 billions... Who needs a parrot! Not me.... not stable ignore you go! After 700 posts enough is enough! Same as Quentin, Angry101... lol!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing